The Diabetes, Cardiorenal, and Metabolic Diseases Task Force practice recommendations suggest, as part of a multispecialty consensus, adding finerenone in combination with an SGLT2 inhibitor to ARB or ACEi therapy for preventing HF and slowing CKD progression in persons with diabetes and CKD [115]. This evidence concerns the gene SLC5A2 and chronic kidney disease.